believe pleased million. the I'm report get quarter over right the that a XXXX. into net in AMPYRA particularly our of Tierney. for that of XX% generic the revenue $XX.X This the becoming financial quarter Thanks, and encouraging everyone. quarter deployed in at the to to contributor run stability an to by revenue and encouraging of cash report. XXXX INBRIJA pandemic. net Acorda's XXXX. light of Welcome, important brand We'll went end of second strategies our likewise XXXX is rate September that We on due That increase to a to the was execute. AMPYRA neutral we're since the basis second of impact was we it of for flow is second goal million. durability was the continuing that AMPYRA $X.X was continuing
business INBRIJA our and trajectory. to Moving
of the scheduled experience As or Levodopa. in had a XX% address regularly of began the sales. net I indicated that return quarter doses in their year-over-year saw medications. of signs as increase the symptoms as reminder, many a INBRIJA Inhaled with to between in is we off-periods And to recede. We people growth second Parkinson's of encouraging mentioned, to pandemic INBRIJA compared XXXX It's
total demand. organic most QX increase in dispensed over We And measured had we XX% growth, increase which accurately prescriptions XXXX. reflects in a importantly, a by XX% also had cartons,
pandemic at-risk how COVID will it to of their with and the visits. resume difficult positions pleased will progress, the continues While predict quickly to how populations course the open we're offices to office quickly make continue
our Spanish announced Esteve in important toward also this commercial the track has pharmaceutical in market. agreement ex-US Esteve our Pharmaceuticals We goal with an record And for ex-US of a products milestone partnerships is INBRIJA. of Spain. first commercializing successful commercialization
As the part of in exchange will world. a in also the other with and of sales for quarter INBRIJA product. territories XXXX. We're the of receive discussions Esteve supply fourth supply rights of double-digit to launch to rest agreement, significant in Acorda expects in active companies in for gross Europe the of additional the INBRIJA percent the
due first of Moving is revenue increased of a AMPYRA franchise the over the by and net over durability XX% that factors. of to decreased quarter this QX XXXX. year X% only believe We AMPYRA. this number about to
First, includes step loyalty on loyal patients education, brand. And program AMPYRA. that their to that the branded physicians commercially and and to provide based support insured remain which the We've we've for continue physician free our relationships. patients on earned care provided call always continuing in first support. AMPYRA that co-pay specialists, also of and insured their mitigation they've MS months get patients we maintained where for also to and field two our commercially and is and team initial strong provide sales And reimbursement
convertible settle the this end at in QX in made that approximately release note to the for quarter XX-Q. I our detail and we $XX goals our and to debt. XXXX. -- that financials our in table more short-term and our financials net press of of the in is million The cash payment Moving are summarized to particular, during of want
key factors: value. patient yield enhance started how we are positive and long-term growth. events We're position We've months to in will the grew Acorda year to we INBRIJA's continuing taken forward. going over six significant continuing prescriptions So steps the add first, on of to the to following the XXXX are drive XXXX build that building in-person status first in experience moving to The value focused commercial long-term later held and results initiatives virtual dispensed the as to this XXX cartons patient of quarter. nicely We pandemic. potentially the in events depending on
to hopefully patients and second and the offices contributed has in-person believe we increases fall materially to field in prescribers access returned see to Our meetings teams we office the the that in that prescriptions the increasing the to pandemic extent regular recede to more effects returning quarter. with to team field the physicians' gain and beyond, expect visits. our To in-person of in
we mentioned as territories US commercialize with agreement the the INBRIJA and several active we're the additional first rest we've and Spain outside to for secured in and of Importantly, in discussions our Europe world. parties
we've Regarding to to by been very support possible maintain we against encouraged generics our field as time, our AMPYRA, And the have to-date. durability the continuing while that calling much decline as expect Offices. and we programs MS brand's by over teams will provide continue brand to to on
value factor discipline continue our fiscal building key forward. going is and reduce expenses to Another continue in to
of this million of to already has expect million receive the about also tax a $X million credit Act approximately We to total which from $X realized. year been CARES $X
FAMPYRA the have of half expect sales Biogen we Acorda second addition, XXXX. royalties ex-US to back to revert the from of on In in
discuss with as tiered already by some the seeking royalties indications Foundation technology now some now in in way for other Gates a also product. be have other EU potential collaborations and been platform. potential to inhaled ARCUS. sales. whom We're the of your for of reminder, open additional It's from net by potential on aiming of to ARCUS. whom funding pediatric expressed by potential the interest collaborations We'll call XXXX. developed in build flow the neutral for already a of plan US with double-digit well questions. of INBRIJA We also ARCUS validated on to run by to the rate approval basis companies interest And surfactant cash discuss companies are on these we're indications the We of expressed end reminder, plan additional a as As have
